Form 4: AnaptysBio Completes First Tracks Biotherapeutics Spin-Off

AnaptysBio, Inc. has completed the spin-off of its subsidiary, First Tracks Biotherapeutics, Inc., distributing all shares of First Tracks common stock to AnaptysBio shareholders.

Summary

• AnaptysBio, Inc. has completed a spin-off transaction involving its subsidiary, First Tracks Biotherapeutics, Inc.
• The spin-off occurred on April 20, 2026, before the market opened.
• AnaptysBio distributed all of its issued and outstanding shares of First Tracks common stock to AnaptysBio's common stock holders.
• As of April 20, 2026, AnaptysBio reported owning 100 shares of First Tracks common stock, which represented all outstanding shares prior to the distribution.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents a corporate restructuring that could lead to future value creation, but the immediate impact is primarily informational.

Positives

• Completion of a strategic spin-off, potentially allowing both entities to focus on their respective core businesses and unlock shareholder value.
• Distribution of all shares to AnaptysBio shareholders, directly benefiting them with ownership in the newly independent First Tracks Biotherapeutics.

Risks

• The success of First Tracks Biotherapeutics as an independent entity is subject to market conditions and its own operational execution.
• Potential for AnaptysBio shareholders to experience dilution if First Tracks Biotherapeutics issues additional shares in the future.
• The value of the distributed shares in First Tracks Biotherapeutics may fluctuate significantly.

Future Outlook

No specific future outlook or guidance for either AnaptysBio or First Tracks Biotherapeutics is provided in this filing.

Management Comments

• "Represents the outstanding shares of common stock of First Tracks as of April 20, 2026, which were distributed in the Spin-Off as defined in footnote 2 on April 20, 2026."

Industry Context

StockSavvy.ai notes that spin-offs are a common strategy in the biotechnology sector to unlock value, allowing specialized companies to pursue distinct strategic paths and attract focused investment.

Stakeholder Impact

• Shareholders of AnaptysBio will receive shares in First Tracks Biotherapeutics, potentially diversifying their investment portfolio.
• Employees of AnaptysBio and First Tracks Biotherapeutics may experience changes in organizational structure and reporting lines.

Next Steps

• AnaptysBio shareholders will now hold shares in both AnaptysBio and First Tracks Biotherapeutics.
• First Tracks Biotherapeutics will operate as an independent entity.

Key Dates

Keywords

Spin-off, AnaptysBio, First Tracks Biotherapeutics, SEC Form 4, Equity Distribution, Corporate Restructuring, Biotechnology